Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Primary and booster MenACWY-TT vaccination in Dutch older adults
NL-OMON54103Phase 4Recruiting
- Sponsor
- National Institute for Public Health and the Environment
- Start
- Jun 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of Meningococcal polysaccharide vaccine group W-135 in meningococcal disease (2 arms), sponsored by National Institute for Public Health and the Environment. Primary endpoint: Functional antibody levels against MenA, MenC, MenW and MenY. Started Jun 2022; status: recruiting.
02
Drugs
Meningococcal polysaccharide vaccine group W-135
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on NL-OMON54103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54103.